Tissue transglutaminase contributes to disease progression in the R6/2 Huntington's disease mouse model via aggregate-independent mechanisms

Journal of Neurochemistry

Volumn 92, Issue 1, 2005, Pages 83-92

  Bailey, Craig D C ^a   Johnson, Gail V W ^a,b  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b Department of Psychiatry   (United States)

Author keywords

Aggregates; Brain; Huntington's disease; Transglutaminase

Indexed keywords

HUNTINGTIN; PROTEIN GLUTAMINE GAMMA GLUTAMYLTRANSFERASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN TISSUE; CELL DEATH; CONTROLLED STUDY; CORPUS STRIATUM; DISEASE COURSE; FEMALE; HUNTINGTON CHOREA; KNOCKOUT MOUSE; MALE; MOTOR DYSFUNCTION; MOUSE; MOUSE STRAIN; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; CELL AGGREGATION; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; FEMALE; GTP-BINDING PROTEINS; HUNTINGTON DISEASE; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MICE, TRANSGENIC; PREGNANCY; PROSENCEPHALON; TRANSGLUTAMINASES;

ANIMALIA;

EID: 13244279859     PISSN: 00223042     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1471-4159.2004.02839.x     Document Type: Article

References (38)

1. Apostol B. L., Kazantsev A., Raffioni S. et al. (2003) A cell-based assay for aggregation inhibitors as therapeutics of polyglutamine-repeat disease and validation in Drosophila. Proc. Natl Acad. Sci. USA 100, 5950-5955.
2. Bailey C. D., Graham R. M., Nanda N., Davies P. J. and Johnson G. V. (2004) Validity of mouse models for the study of tissue transglutaminase in neurodegenerative diseases. Mol. Cell. Neurosci. 25, 493-503.
3. Bates G. (2003) Huntingtin aggregation and toxicity in Huntington's disease. Lancet 361, 1642-1644.
4. Burke M. G., Woscholski R. and Yaliraki S. N. (2003) Differential hydrophobicity drives self-assembly in Huntington's disease. Proc. Natl Acad. Sci. USA 100, 13 928-13 933.
5. Chun W., Lesort M., Tucholski J., Faber P. W., MacDonald M. E., Ross C. A. and Johnson G. V. (2001a) Tissue transglutaminase selectively modifies proteins associated with truncated mutant huntingtin in intact cells. Neurobiol. Dis. 8, 391-404.
6. Chun W., Lesort M., Tucholski J., Ross C. A. and Johnson G. V. (2001b) Tissue transglutaminase does not contribute to the formation of mutant huntingtin aggregates. J. Cell Biol. 153, 25-34.
7. Davies S. W., Turmaine M., Cozens B. A., DiFiglia M., Sharp A. H., Ross C. A., Scherzinger E., Wanker E. E., Mangiarini L. and Bates G. P. (1997) Formation of neuronal intranuclear inclusions underlies the neurological dysfunction in mice transgenic for the HD mutation. Cell 90, 537-548.
8. Dedeoglu A., Kubilus J. K., Jeitner T. M. et al (2002) Therapeutic effects of cystamine in a murine model of Huntington's disease. J. Neurosci. 22, 8942-8950.
9. Hockly E., Woodman B., Mahal A., Lewis C. M. and Bates G. (2003) Standardization and statistical approaches to therapeutic trials in the R6/2 mouse. Brain Res. Bull. 61, 469-479.
10. Huntington's Disease Collaborative Research Group (1993) A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell 72, 971-983.
11. Jeitner T. M., Bogdanov M. B., Matson W. R. et al. (2001) N (epsilon)-(gamma-L-glutamyl)-L-lysine (GGEL) is increased in cerebrospinal fluid of patients with Huntington's disease. J. Neurochem. 79, 1109-1112.
12. Kahlem P., Green H. and Djian P. (1998) Transglutaminase action imitates Huntington's disease: selective polymerization of Huntingtin containing expanded polyglutamine. Mol. Cell 1, 595-601.
13. Karpuj M. V., Garren H., Slunt H., Price D. L., Gusella J., Becher M. W. and Steinman L. (1999) Transglutaminase aggregates huntingtin into nonamyloidogenic polymers, and its enzymatic activity increases in Huntington's disease brain nuclei. Proc. Natl Acad. Sci. USA 96, 7388-7393.
14. Karpuj M. V., Becher M. W., Springer J. E., Chabas D., Youssef S., Pedotti R., Mitchell D. and Steinman L. (2002) Prolonged survival and decreased abnormal movements in transgenic model of Huntington disease, with administration of the transglutaminase inhibitor cystamine. Nat. Med. 8, 143-149.
15. Kim M., Lee H. S., Laforet G. et al. (1999) Mutant huntingtin expression in clonal striatal cells: dissociation of inclusion formation and neuronal survival by caspase inhibition. J. Neurosci. 19, 964-973.
16. Kuemmerle S., Gutekunst C. A., Klein A. M., Li X. J., Li S. H., Beal M. F., Hersch S. M. and Ferrante R. J. (1999) Huntington aggregates may not predict neuronal death in Huntington's disease. Ann. Neurol. 46, 842-849.
17. Lai T. S., Tucker T., Burke J. R., Strittmatter W. J. and Greenberg C. S. (2004) Effect of tissue transglutaminase on the solubility of proteins containing expanded polyglutamine repeats. J. Neurochem. 88, 1253-1260.
18. Lesort M., Chun W., Johnson G. V. and Ferrante R. J. (1999) Tissue transglutaminase is increased in Huntington's disease brain. J. Neurochem. 73, 2018-2027.
19. Lesort M., Tucholski J., Miller M. L. and Johnson G. V. (2000) Tissue transglutaminase: a possible role in neurodegenerative diseases. Prog. Neurobiol. 61, 439-463.
20. Lesort M., Lee M., Tucholski J. and Johnson G. V. (2003) Cystamine inhibits caspase activity. Implications for the treatment of polyglutamine disorders. J. Biol. Chem. 278, 3825-3830.
21. Lorand L. and Graham R. M. (2003) Transglutaminases: crosslinking enzymes with pleiotropic functions. Nat. Rev. Mol. Cell. Biol. 4, 140-156.
22. Maccioni R. B. and Seeds N. W. (1986) Transglutaminase and neuronal differentiation. Mol. Cell Biochem. 69, 161-168.
23. Mangiarini L., Sathasivam K., Seller M. et al. (1996) Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell 87, 493-506.
24. Mastroberardino P. G., Iannicola C., Nardacci R., De Bernassola F. L. V., Melino G., Moreno S., Pavone F., Oliverio S., Fesus L. and Piacentini M. (2002) 'Tissue' transglutaminase ablation reduces neuronal death and prolongs survival in a mouse model of Huntington's disease. Cell Death Differ. 9, 873-880.
25. Melino G., Annicchiarico-Petruzzelli M., Piredda L., Candi E., Gentile V., Davies P. J. and Piacentini M. (1994) Tissue transglutaminase and apoptosis: sense and antisense transfection studies with human neuroblastoma cells. Mol. Cell. Biol. 14, 6584-6596.
26. Nanda N., Iismaa S. E., Owens W. A., Husain A., Mackay F. and Graham R. M. (2001) Targeted inactivation of Gh/tissue transglutaminase II. J. Biol. Chem. 276, 20 673-20 678.
27. Oliverio S., Amendola A., Rodolfo C., Spinedi A. and Piacentini M. (1999) Inhibition of 'tissue' transglutaminase increases cell survival by preventing apoptosis. J. Biol. Chem. 274, 34 123-34 128.
28. Pastuszko A., Wilson D. F. and Erecinska M. (1986) A role for transglutaminase in neurotransmitter release by rat brain synaptosomes. J. Neurochem. 46, 499-508.
29. Perutz M. F., Johnson T., Suzuki M. and Finch J. T. (1994) Glutamine repeats as polar zippers: their possible role in inherited neurodegenerative diseases. Proc. Natl Acad. Sci. USA 91, 5355-5358.
30. Piacentini M., Annicchiarico-Petruzzelli M., Oliverio S., Piredda L., Biedler J. L. and Melino E. (1992) Phenotype-specific 'tissue' transglutaminase regulation in human neuroblastoma cells in response to retinoic acid: correlation with cell death by apoptosis. Int. J. Cancer 52, 271-278.
31. Pollitt S. K., Pallos J., Shao J., Desai U. A., Ma A. A., Thompson L. M., Marsh J. L. and Diamond M. I. (2003) A rapid cellular FRET assay of polyglutamine aggregation identifies a novel inhibitor. Neuron 40, 685-694.
32. Sanchez I., Mahlke C. and Yuan J. (2003) Pivotal role of oligomerization in expanded polyglutamine neurodegenerative disorders. Nature 421, 373-379.
33. Saudou F., Finkbeiner S., Devys D. and Greenberg M. E. (1998) Huntingtin acts in the nucleus to induce apoptosis but death does not correlate with the formation of intranuclear inclusions. Cell 95, 55-66.
34. Tanaka M., Machida Y., Niu S., Ikeda T., Jana N. R., Doi H., Kurosawa M., Nekooki M. and Nukina N. (2004) Trehalose alleviates polyglutamine-mediated pathology in a mouse model of Huntington disease. Nat. Med. 10, 148-154.
35. Tucholski J. and Johnson G. V. (2002) Tissue transglutaminase differentially modulates apoptosis in a stimuli-dependent manner. J. Neurochem. 81, 780-791.
36. Tucholski J., Lesort M. and Johnson G. V. (2001) Tissue transglutaminase is essential for neurite outgrowth in human neuroblastoma SH-SY5Y cells. Neuroscience 102, 481-491.
37. Yang W., Dunlap J. R., Andrews R. B. and Wetzel R. (2002) Aggregated polyglutamine peptides delivered to nuclei are toxic to mammalian cells. Hum. Mol. Genet. 11, 2905-2917.
38. Yu Z. X., Li S. H., Nguyen H. P. and Li X. J. (2002) Huntingtin inclusions do not deplete polyglutamine-containing transcription factors in HD mice. Hum. Mol. Genet. 11, 905-914.